東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Kinesins and cancer

Kozielski, Frank.

FindBook

Google Book

Amazon

博客來

Kinesins and cancer

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Kinesins and cancer/ edited by Frank Kozielski.
其他作者:	Kozielski, Frank.
出版者:	Dordrecht :Springer Netherlands : : 2015.,
面頁冊數:	x, 271 p. :ill., digital ;24 cm.
內容註:	Preface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy? -- Down-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target -- Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index.
Contained By:	Springer eBooks
標題:	Kinesin. -
電子資源:	http://dx.doi.org/10.1007/978-94-017-9732-0
ISBN:	9789401797320 (electronic bk.)

Kinesins and cancer
Kinesins and cancer[electronic resource] /edited by Frank Kozielski. - Dordrecht :Springer Netherlands :2015. - x, 271 p. :ill., digital ;24 cm.

Preface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy? -- Down-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target -- Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index.

This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.

ISBN: 9789401797320 (electronic bk.)

Standard No.: 10.1007/978-94-017-9732-0doiSubjects--Topical Terms:

2139058
Kinesin.

LC Class. No.: QP552.K46

Dewey Class. No.: 572.6

Kinesins and cancer
LDR:03040nmm a2200313 a 4500 001 1997729
003 DE-He213
005 20151008150649.0
006 m d
007 cr nn 008maaau
008 151112s2015 ne s 0 eng d
020 $a 9789401797320 (electronic bk.)
020 $a 9789401797313 (paper)
024 7 $a 10.1007/978-94-017-9732-0 $2 doi
035 $a 978-94-017-9732-0
040 $a GP $c GP
041 0 $a eng
050 4 $a QP552.K46
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 572.6 $2 23
090 $a QP552.K46 $b K51 2015
245 0 0 $a Kinesins and cancer $h [electronic resource] / $c edited by Frank Kozielski.
260 $a Dordrecht : $b Springer Netherlands : $b Imprint: Springer, $c 2015.
300 $a x, 271 p. : $b ill., digital ; $c 24 cm.
505 0 $a Preface -- The kinesin superfamily -- The discovery and development of Eg5 inhibitors for the clinic -- Mechanism of action of Eg5 inhibitors -- Clinical trials of mitotic kinesin inhibitors -- Kif15; a useful target for anti-cancer therapy? -- Down-regulating CENP-E activity: for better or for worse -- The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug target -- Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapy -- Chromokinesins in genome maintenance and cancer -- Kif14: a clinically relevant kinesin and potential target for cancer therapy -- Kinesin-8 members and their potential as biomarker or therapeutic target -- The kinesin-6 members MKLP1, MKLP2 and MPP -- Non-motor spindle proteins as cancer chemotherapy targets -- Inhibitors of mitotic kinesins for cancer treatment: consequences for neurons -- Index.
520 $a This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development. Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future. The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.
650 0 $a Kinesin. $3 2139058
650 0 $a Antineoplastic agents $x Development. $3 752563
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Cell Biology. $3 892383
650 2 4 $a Medicinal Chemistry. $3 892420
650 2 4 $a Protein-Ligand Interactions. $3 1006101
650 2 4 $a Oncology. $3 751006
700 1 $a Kozielski, Frank. $3 2139057
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-94-017-9732-0
950 $a Biomedical and Life Sciences (Springer-11642)